Tags: vedolizumab
Review of the Landmark VARSITY Trial
G&H Why is the VARSITY trial still important and clinically relevant? BF The VARSITY trial was a landmark study that provided many insights into the treatment […]
Positioning Biologic Therapies in the Management of Pediatric Inflammatory Bowel Disease
Abstract: The incidence and prevalence of pediatric inflammatory bowel disease (IBD) are rising worldwide, with a steep increase in children under 5 years of age. […]
Gastro-Hep News
Esophageal DNA Test Granted US Food and Drug Administration Breakthrough Device Status The US Food and Drug Administration (FDA) has granted Breakthrough Device status to […]
Vedolizumab-Induced De Novo Extraintestinal Manifestations
Abstract: Background: Vedolizumab is an α4β7 integrin antagonist with gut-specific effects on lymphocyte and monocyte trafficking. Although the treatment is beneficial for inflammatory bowel disease (IBD), […]
Gastro-Hep News
US Preventive Services Task Force Reaffirms Hepatitis B Virus Screening in Pregnant Women All pregnant women should still b8e screened for hepatitis B virus (HBV) infection […]
Use of Vedolizumab for the Treatment of Crohn’s Disease
G&H How does vedolizumab work? BB Vedolizumab (Entyvio, Takeda) works by interfering with lymphocyte trafficking in the gastrointestinal tract. Specifically, it binds to the α4β7 […]
Safety and Positioning of Vedolizumab in Patients With Inflammatory Bowel Disease
G&H How safe is vedolizumab? What is its side-effect profile? BF Most drugs used to treat inflammatory bowel disease (IBD) are systemically immunosuppressive, which means […]